FDA Grants Orphan Drug Exclusivity for YUVIWEL, Now Commercially Available in US

summarizeSummary

Ascendis Pharma announced that its drug YUVIWEL received Orphan Drug Exclusivity from the FDA and is now commercially available in the United States, securing market protection until 2033.

check_boxKey Events

• Orphan Drug Exclusivity Granted

  YUVIWEL (navepegritide) received Orphan Drug Exclusivity (ODE) from the U.S. FDA, providing market protection through February 27, 2033.

• Commercial Availability in U.S.

  YUVIWEL is now commercially available in the United States, marking a key step for revenue generation.

• First and Only Once-Weekly Treatment

  YUVIWEL is the first and only FDA-approved once-weekly treatment for increasing linear growth in children with achondroplasia, offering continuous systemic exposure to CNP.

auto_awesomeAnalysis

This 6-K filing officially announces a significant regulatory and commercial milestone for Ascendis Pharma. The grant of Orphan Drug Exclusivity (ODE) by the FDA for YUVIWEL (navepegritide) provides market protection until February 27, 2033, securing a competitive advantage for the company's new treatment for achondroplasia. The immediate commercial availability in the U.S. means the company can begin generating revenue from this product. While the news was previously reported by Dow Jones Newswires on the same day, this filing serves as the official company disclosure to the SEC, confirming the details of this important development.